Clinical trials: Huntington's Disease
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Huntington Disease, Chorea
Citalopram to Enhance Cognition in HD
This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1.
- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Trial name
- CIT-HD (NCT00271596)
- Testing
- 20mg daily citalopram
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Huntington's Disease
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease…
- Trial name
- NCT02231580
- Testing
- BN82451B
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ipsen
Huntington Disease
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with, or at risk for, manifest Huntington's Disease (HD).
- Trial name
- NCT04514367
- Testing
- ANX005
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Annexon, Inc.
Huntington's Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
- Trial name
- NCT03342053
- Testing
- RO7234292 (RG6042)
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Huntington's Disease
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
- Trial name
- Open PRIDE-HD (NCT02494778)
- Testing
- Pridopidine
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 248 people
- Sponsor
- Prilenia
Huntington's Disease
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in…
- Trial name
- PRECISION-HD1 (NCT03225833)
- Testing
- WVE-120101
- Where
- 21 sites in Australia, Canada and 5 more
- Volunteers
- 61 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Huntington's Disease
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
- Trial name
- MermaiHD (NCT00665223)
- Testing
- ACR16
- Where
- 31 sites in Austria, Belgium and 6 more
- Volunteers
- 437 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Huntington's Disease
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
- Trial name
- NCT03664804
- Testing
- No Study Drug was Administered in this Study
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Chorea Associated With Huntington Disease
Alternatives for Reducing Chorea in Huntington Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of SD-809 extended release (ER) in participants switching from tetrabenazine to SD-809 ER.
- Trial name
- ARC-HD (NCT01897896)
- Testing
- SD-809
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 119 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates.
- Trial name
- NCT01451463
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University
Huntington Disease
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease
The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglycerides (fats), as a treatment for Huntington's disease (HD).
- Trial name
- NCT03515213
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Irvine
Huntington Disease
Study of WVE-003 in Patients With Huntington's Disease
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who…
- Trial name
- NCT05032196
- Testing
- SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003
- Where
- 23 sites in Australia, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington Disease
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
- Trial name
- NCT05358717
- Testing
- PTC518
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Irritable Mood, Huntington's Disease
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease.
- Trial name
- NCT02507284
- Testing
- SRX246
- Where
- 22 sites in United States
- Volunteers
- 106 people
- Sponsor
- Azevan Pharmaceuticals
Huntington's Disease
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
- Trial name
- PREQUEL (NCT00920699)
- Testing
- CoQ10
- Where
- 13 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University